Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 229

1.

Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.

Stern BJ, Royal W 3rd, Gelfand JM, Clifford DB, Tavee J, Pawate S, Berger JR, Aksamit AJ, Krumholz A, Pardo CA, Moller DR, Judson MA, Drent M, Baughman RP.

JAMA Neurol. 2018 Dec 1;75(12):1546-1553. doi: 10.1001/jamaneurol.2018.2295.

PMID:
30167654
2.

Multisystemic manifestations of sarcoidosis and comorbidities.

Korsten P, Drent M.

Curr Opin Pulm Med. 2018 Sep;24(5):477-478. doi: 10.1097/MCP.0000000000000505. No abstract available.

PMID:
30004993
3.

Nutrition and corticosteroids in the treatment of sarcoidosis.

Bast A, Semen KO, Drent M.

Curr Opin Pulm Med. 2018 Sep;24(5):479-486. doi: 10.1097/MCP.0000000000000501.

PMID:
29939865
4.

The Fatigue Assessment Scale: quality and availability in sarcoidosis and other diseases.

Hendriks C, Drent M, Elfferich M, De Vries J.

Curr Opin Pulm Med. 2018 Sep;24(5):495-503. doi: 10.1097/MCP.0000000000000496.

PMID:
29889115
5.

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis.

de Brouwer B, Drent M, van den Ouweland JMW, Wijnen PA, van Moorsel CHM, Bekers O, Grutters JC, White ES, Janssen R.

Respir Res. 2018 Mar 20;19(1):45. doi: 10.1186/s12931-018-0747-6.

6.

Pharmacogenetic variants and vitamin K deficiency: a risk factor or trigger for fibrosing interstitial pneumonias?

Drent M, Wijnen P, Bast A.

Curr Opin Pulm Med. 2018 May;24(3):287-295. doi: 10.1097/MCP.0000000000000467.

PMID:
29538081
7.

Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study.

Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J.

Respir Med. 2018 May;138S:S24-S30. doi: 10.1016/j.rmed.2017.11.008. Epub 2017 Nov 20.

PMID:
29239767
8.

The disturbed redox-balance in pulmonary fibrosis is modulated by the plant flavonoid quercetin.

Veith C, Drent M, Bast A, van Schooten FJ, Boots AW.

Toxicol Appl Pharmacol. 2017 Dec 1;336:40-48. doi: 10.1016/j.taap.2017.10.001. Epub 2017 Oct 4.

9.

The necessity of external validation in exhaled breath research: a case study of sarcoidosis.

Fijten RRR, Smolinska A, Drent M, Dallinga JW, Mostard R, Pachen DM, van Schooten FJ, Boots AW.

J Breath Res. 2017 Nov 29;12(1):016004. doi: 10.1088/1752-7163/aa8409.

PMID:
28775245
10.

Small fiber neuropathy: a disabling and underrecognized syndrome.

Voortman M, Fritz D, Vogels OJM, Eftimov F, van de Beek D, Brouwer MC, Drent M.

Curr Opin Pulm Med. 2017 Sep;23(5):447-457. doi: 10.1097/MCP.0000000000000413. Review.

PMID:
28639956
11.

Many faces of neurosarcoidosis: from chronic meningitis to myelopathy.

Fritz D, Voortman M, van de Beek D, Drent M, Brouwer MC.

Curr Opin Pulm Med. 2017 Sep;23(5):439-446. doi: 10.1097/MCP.0000000000000401. Review.

PMID:
28598872
12.

Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.

Bhidayasiri R, Boonpang K, Jitkritsadakul O, Calne SM, Henriksen T, Trump S, Chaiwong S, Susang P, Boonrod N, Sringean J, van Laar T, Drent M, Chaudhuri KR.

Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S49-S55. doi: 10.1016/j.parkreldis.2016.11.014. Epub 2016 Dec 9. Review.

PMID:
27939324
13.

Physical activity and training in sarcoidosis: review and experience-based recommendations.

Strookappe B, Saketkoo LA, Elfferich M, Holland A, De Vries J, Knevel T, Drent M.

Expert Rev Respir Med. 2016 Oct;10(10):1057-68. doi: 10.1080/17476348.2016.1227244. Epub 2016 Sep 8. Review.

PMID:
27552344
14.

Repositioning 'old' drugs to treat rare diseases: arguing from the mechanism of action.

Drent M, Bast A, Bootsma HP, Deneer V.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Aug 1;33(2):191-4. No abstract available.

PMID:
27537726
15.

Sarcoidosis in America. Analysis Based on Health Care Use.

Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, Judson MA, Wolff G.

Ann Am Thorac Soc. 2016 Aug;13(8):1244-52. doi: 10.1513/AnnalsATS.201511-760OC.

PMID:
27509154
16.

Predictors of fatigue in sarcoidosis: The value of exercise testing.

Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M.

Respir Med. 2016 Jul;116:49-54. doi: 10.1016/j.rmed.2016.05.010. Epub 2016 May 12.

17.

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.

Crommelin HA, van der Burg LM, Vorselaars AD, Drent M, van Moorsel CH, Rijkers GT, Deneer VH, Grutters JC.

Respir Med. 2016 Jun;115:72-7. doi: 10.1016/j.rmed.2016.04.011. Epub 2016 Apr 23.

18.

Pulmonary alveolar proteinosis: another autoimmune disease associated with sarcoidosis?

Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Hetzel M, Drent M, Bonella F.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):90-4.

PMID:
27055841
19.

Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.

Van Manen MJ, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, Gosker HR, Birring SS, Patel AS, van den Toorn L, van den Blink B, Boomars K, Hoitsma E, Wijsenbeek MS.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):75-82.

PMID:
27055839
20.

Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.

Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, Lo KH, Barnathan ES; Sarcoidosis Investigators.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):289-95.

PMID:
26847095

Supplemental Content

Loading ...
Support Center